Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy
NCT06253221Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Started Apr 2024; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06253221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253221.